{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', 'Table 1. Summary of Demographic and Baseline Characteristics (continued)', 'Table 2: Patients with Adverse Events in the Injected Knee Regardless of Relatedness', 'Parameter/Category', 'Synvisc-One', 'Saline Control', 'Total', '(continued)', '(N=124)', '(N=129)', '(N=253)', 'Synvisc-One', 'Saline Control', 'MedDRA Preferred Term', 'N=123', 'N=130', 'Prior Arthroscopy In', '123', '130', '253', 'Target Knee, n f', 'n (%)', 'n (%)', 'Arthropathy', '1 (0.8%)', '0', 'Yes (%)', '26 (21%)', '28 (22%)', '54 (21%)', 'Gait disturbance', '1 (0.8%)', '0', 'Tibio-Femoral Joint', 'Modified Kellgren-', 'Joint range of motion decreased', '0', '1 (0.8%)', 'Lawrence Numerical', 'Grading System', 'Ostheoarthrifis', '0', '1 (0.8%)', 'Grade Il', '63 (51%)', '51 (39%)', '114 (45%)', 'Note: Patients are counted once for each unique AE regardless of device relatedness, and may have', 'had more than one unique AE', 'Grade III', '60 (49%)', '78 (60%)', '138 (55%)', 'Grade IV', '0', '1 (1%)', '1 (0%)', 'Table 3: Patients with Device-Related Adverse Events in the Injected Knee', 'Total WOMAC Score', '55.1 (10.5)', '54.8 (9.4)', 'Synvisc-One', 'Saline Control', '(0-96); Mean (SD)', 'MedDRA Preferred Term', 'N=123', 'N=130', 'WOMAC A Score', '2.30 (0.43)', '225 (0.41)', 'n (%)', 'n (%)', '(0-4); Mean (SD)', 'Any Device-Related Adverse Event', '7 (5.7%)', '4 (3.1%)', 'PTGA Mean (SD)', '2.57 (0.67)', '2.50 (0.64)', '(0-4)', 'Arthralgia', '2 (1.6%)', '3 (2.3%)', 'COGA Mean (SD)', '2.44 (0.76)', '2,49 (0.75)', 'Arthritis', '1 (0.8%)', '0', '(0-4)', 'Arthropathy', '1 (0.8%)', '0', '*ITT Population', 'Injection site pein', '1 (0.8%)', '1 (0.8%)', 'Population', 'Joint effusion', '2 (1.6%)', '0', 'Table 2: Patients with Adverse Events in the injected Knee Regardless of Relatedness', 'Note: Patients are counted once for each unique AE, and may have had more than one unique AE', 'Synvisc-One', 'Saline Control', 'MedDRA Preferred Term', 'N=123', 'N=130', 'Table 4. Primary Efficacy Results: WOMAC A (Pain) Score Overall Change from Basellne', 'n (%)', 'n (%)', 'over 26 Weeks - ITT Population', 'Any Treatment-Emergent Adverse', 'Baseline', 'Mean Post-', 'Estimated', 'Estimated', 'p-value', 'Event', '44 (36.8%)', '44 (33.8%)', 'Mean (SE)', 'treatment (SE)', 'Change', 'Difference', '(ANCOVA)', 'Arthralgia', '31 (25.2%)', '28 (21.5%)', '(0-4 Scale)', '(0-4 Scale)', '(SE)', 'from Saline', 'Contol (95%', 'Joint stiffness', '10 (8.1%)', '13 (10.0%)', 'CI)', 'Joint effusion', '7 (5.7%)', '7 (5.4%)', 'Synvisc-', 'One*', 'Joint swelling', '5 (4.1%)', '7 (5.4%)', '(n=124)', '2.30 (0.04)', '1.43 (0.06)', '-0.84 (0.06)', '0,15', '(-0.302,', '0.047', 'Joint warmth', '2 (1.6%)', '5 (3.8%)', 'Saline', '-0.002)', 'Control', 'Post-traumatic pain', '0', '3 (2.3%)', '(n=129)', '2.25 (0.04)', '1,59 (0.06)', '-0,69 (0.06)', 'Injection site pain', '1 (0.8%)', '1 (0.8%)', 'WOMAC A scale using 5 point Likert scale, where 0 = no pain and 4 = extreme pain', 'Synovial cyst', '0', '2 (1.5%)', 'Repeated measures Analysis of Covariance was used for the WOMAC A pain score change from the', 'baseline.', 'Arthrifis', '1 (0.8%)', '0', 'Table 5. Clinical Meaning of Secondary Efficacy Endpoints', 'Odds Ratio\"', 'Definition', 'Explanation', 'Generalized Estimating Equation for categorical', 'data', 'Over', '0,64\u00b0', 'The odds (probability [Worse] / Probability [Better] for Synvisc-One', 'Synvisc-One patients were 1,56 times more likely to self-report pain', '26 weeks', 'for over 26 weeks and at 26 weeks is approximately 64%, and 56%,', 'relief while walking on a flat surface compared to those patients', 'WOMAC A1', '0,56', 'respectively, to the odds for control.', 'treated with saline control over 26 weeks and 1.79 fimes more likely', 'At week 26', 'to self-report pain relief while walking on a flat surface compared to', 'those patients treated with saline control at 26 weeks', 'Over 26 weeks', '0,69\u00b0', 'The odds (probability [Worse] / Probability [Better]) for Synvisc-One', 'Synvisc-One patients were 1.45 fimes more likely to self-report', 'for over 26 weeks and at 26 weeks is approximately 69% and 51%,', 'improvement in overall health status compared to those patients', 'PTGA', 'At week 26', '0,51t', 'respectively, to the odds for control', 'treated with saline control over 26 weeks and 1.96 fimes more likely', 'PTGA: Patient Global Assessment has 5 scales (Very well, Well, Fair,', 'to self-report improvement in overal health status compared to those', 'Poor, Very poor)', 'patients treated with saline control at 26 weeks', 'Over 26 weaks', '0,71\u00b0', 'The odds (probability [Worse] / Probability [Better] for Synvisc-One', 'Blinded cinical observers were 1.41 times more likely to assess', '0,56', 'for over 26 weeks and at 26 weeks is approximately 71%, and 56%,', 'patients treated with Synvisc-One as showing overall improvement in', 'At week 26', 'COGA', 'respectively, to the odds for control.', 'disease status compared to those pafients treated with saline control', 'COGA: Clinical Observer Global Assessment has 5 scales (Very well,', 'over 26 weeks and 1,79 times more likely to assess patients treated', 'Well, Fair, Poor, Very poor)', 'with Synvisc-One as showing overall improvement in disease status', 'compared to those patients treated with saline control at 26 weeks.', 'OMERACT-OARSI', 'Over 26 weeks', '0.66', 'This response analysis did not reach statistical significance between,', 'Responder', 'the treatment groups.', 'At week 26', '0,69', '4', 'version #: 4.U', 'Page o I OT 02', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}